Loading...
ROCO
4131
Market cap38mUSD
Oct 08, Last price  
31.20TWD
1D
1.63%
1Q
-4.88%
Jan 2017
125.27%
IPO
-78.24%
Name

DR.Chip Biotechnology Inc

Chart & performance

D1W1MN
ROCO:4131 chart
P/E
—
P/S
5.07
EPS
—
Div yield, %
—
Shrs. gr., 5y
15.81%
Rev. gr., 5y
21.25%
Revenues
245m
+297.52%
104,489,00093,345,00088,926,00088,968,00064,729,00061,545,000244,656,000
Net income
-34m
L-28.86%
-11,865,000-27,096,000-17,197,000-28,215,000-64,645,000-48,137,000-34,245,000
CFO
-21m
L-63.83%
-4,334,000-27,769,000-17,154,000-2,689,000-63,883,000-57,154,000-20,670,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NeoCore Technology Co., Ltd. is primarily engaged in the creation, manufacture, and distribution of biochips and advanced rapid nucleic acid hybridization devices. Their extensive product range features systems designed for food safety screening, human diagnostic arrays, agricultural analysis, and specific food examination arrays, in addition to a variety of laboratory instruments and DNA kits. The company further provides a suite of services, encompassing laboratory planning, design, and additional specialized support. Beyond its core biotech operations, NeoCore also participates in the wholesale and retail market for contact lenses. The firm, which was established in 1987 and is based in Tainan, Taiwan, underwent a name change in July 2023, transitioning from its former identity as DR. Chip Biotechnology Incorporation to its current name.

Key people

Wensheng Ji
General Manager, Corporate Governance Officer · since 2023
Weizhe Lu
Head of Finance & Accounting · since 2022
Guoming Hong
Director · since 2022
Director · since 2025
Taiji Zhou
Director · since 2025
Dingmao Zhou
Chairman of the Board, Chief R&D Officer · since 2023
Yongchong Zhuo
Director · since 2022
Xueling Cai
Independent Director · since 2022
Independent Director · since 2022
Chunhui Zhu
Independent Director · since 2025
IPO date
Mar 12, 2003
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT